Human Metabolome Technologies, Inc.

Human Metabolome Technologies, Inc.

TTSE:6090
559.00
JPY
-1.00
(-0.18%)
3.33BMarket Cap
Feb 18Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
130.23
146.39
160.34
161.34
142.66
- -
190.81
190.64
207.33
220.02
227.58
255.62
253.4
- -
Basic EPS, GAAP
-6.59
-13.41
-10.86
-26.92
-61.57
- -
-8.15
9.87
45.39
48.39
41.14
45.05
35.71
- -
Free Cash Flow per Basic Share
-7.18
-14.4
1.79
-46.01
-61.69
- -
25.46
-10.52
30.15
28.47
34.28
39.49
22.31
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.93
15.53
15.15
- -
Book Value per Share
297.51
285.59
320.05
300.57
245.61
207.46
206.13
213.57
251.95
300.04
329.08
335.3
337.45
337.45
Tangible Book Value per Share
296.59
284.99
319.28
299.04
243.49
205.76
205
212.78
250.92
296.35
326.13
333.05
331.32
331.32
Basic Weighted Avg Shares
5
5
6
6
6
6
6
6
6
6
6
6
6
6
Sales/Revenue/Turnover
687
780
914
938
834
- -
1,118
1,124
1,223
1,299
1,346
1,455
1,422
- -
Operating Margin (%)
-14.64
-9.02
-4.74
-15.02
-43.79
- -
-1.52
3.5
15.63
16.24
16.36
17.15
14.76
- -
Depreciation Expense
71
61
53
61
64
- -
48
56
65
80
86
104
111
- -
Net Income, GAAP
-35
-71
-62
-157
-360
- -
-48
58
268
286
243
256
200
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.12
4.94
10.83
- -
Profit Margin (%)
-5.06
-9.16
-6.77
-16.68
-43.16
- -
-4.27
5.18
21.89
21.99
18.08
17.62
14.09
- -
Working Capital
1,497
1,342
1,689
1,641
1,232
1,098
1,111
1,140
1,196
1,355
1,463
1,415
1,329
1,329
LT Debt
31
6
- -
32
22
20
10
33
23
13
11
3
- -
- -
Total Equity
1,583
1,523
1,859
1,753
1,437
1,214
1,215
1,260
1,487
1,772
1,947
1,909
1,829
1,829
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
9.73
11.23
9.4
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.75
12.35
10.23
- -
Return on Common Equity (%)
-2.22
-4.6
-3.66
-8.67
-22.57
- -
-3.93
4.7
19.5
17.54
13.08
13.3
10.72
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Dec'26
Jun'26
ST Debt
- -
102
104
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
4
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
5
Market Capitalization
4,245
3,714
3,328

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Dec'26
Jun'26
Total Current Assets
- -
1,647
1,768
Cash, Cash Equivalents & STI
- -
1,209
1,444
Accounts Receivable, Net
- -
360
258
Inventories
- -
40
28
Total Current Liabilities
- -
313
439
Payables & Accruals
- -
- -
- -
ST Debt
- -
102
104
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.54%
8.18%
-4.17%
Free Cash Flow
- -
-81.02%
-44.3%
Net Income, GAAP
- -
67.08%
-21.86%
Sales/Revenue/Turnover
- -
4.89%
-2.27%
Total Cash Common Dividend
- -
- -
-3.83%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
398
483
230
1,346
2025
- -
- -
- -
- -
1,455
2026
- -
- -
- -
- -
1,422

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6.47
18.47
26.63
2.48
41.14
2025
- -
- -
- -
- -
45.05
2026
- -
- -
- -
- -
35.71

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
9.93
2025
- -
- -
- -
- -
15.53
2026
- -
- -
- -
- -
15.15

Company Description

CEO
Yasuhiro Ohata
Full Time Employees
65
Sector
Health technology
Industry
Biotechnology
Address
246-2 Mizukami Kakuganji Tsuruoka YA Japan 997-0052
IPO Date
Dec 24, 2013
Business
Human Metabolome Technologies, Inc. (Ticker: 6090.T) is a biotechnology company specializing in metabolomics research and analysis services. The company provides comprehensive metabolome analysis, including mass spectrometry-based metabolic profiling; targeted and non-targeted metabolomics; biomarker discovery; clinical trial support; and reagent development for metabolomics research. Its core offerings encompass human, animal, and microbial metabolome analysis services aimed at pharmaceutical, academic, and industrial clients worldwide. Human Metabolome Technologies operates primarily in Japan and internationally, supporting drug development, diagnostics, and life science research since its founding in 2003 and is headquartered in Tsuruoka, Yamagata, Japan. In the last 1-2 years, the company has expanded its service portfolio with enhanced metabolite databases and reagent product launches aimed at improving research accuracy and throughput, alongside forming strategic collaborations with global pharmaceutical and academic institutions to bolster metabolomics applications. These partnerships focus on advancing precision medicine through metabolic biomarker discovery and application in therapeutic development. Human Metabolome Technologies continues to adapt to market demands by leveraging advanced analytical technologies and expanding its global footprint in metabolomics solutions. The company operates within the biotechnology and life sciences industries, targeting pharmaceutical companies, research institutions, and healthcare sectors. It maintains subsidiaries and collaborative networks to enhance its research capabilities and service delivery. Human Metabolome Technologies integrates cutting-edge technology with biological data analysis to offer robust metabolomics solutions facilitating innovation in medical and biological research.